Experienced CNS Industry Executive Eliseo Salinas, MD, MSc, Joins Pioneering Neuroscience Company BOSTON, Sept. 22, 2022 /PRNewswire/ — Delix Therapeutics (the “Company”), a neuroscience company developing novel disease-modifying therapeutics for psychiatric and neurological conditions, today announced the appointment of Dr. Eliseo Salinas as Head of Research & Development (R&D). Dr.


Previous articleNuminus Expands Ketamine Therapy for Mental Health in Montreal and announces new brand awareness initiativesUSA – EnglishUSA – EnglishUSA – EnglishEspaña – españolLatin America – español
Next articlePT358 – Dr. Rick Barnett, Psy.D – Contexts of Use: Exploring the Various Paradigms of Psychedelics